<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128322</url>
  </required_header>
  <id_info>
    <org_study_id>128HT09K</org_study_id>
    <nct_id>NCT01128322</nct_id>
  </id_info>
  <brief_title>CKD-828 Primary Hypertension Trial(Dose-selection)</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to determine the best dose combination of S-Amlodipine and&#xD;
      Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a&#xD;
      once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their&#xD;
      monotherapy components and placebo, in patients with stage I or II essential hypertension(a&#xD;
      mean seated cuff diastolic blood pressure &gt;=95 and &lt;=115 mmHg).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure(MSDBP)</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure(MSDBP)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure(MSSBP)</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
    <description>Reduction SBP &lt; 140mmHg, DBP &lt; 90mmHg</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Amlodipine, Telmisartan</intervention_name>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_label>S-Amlodipine 2.5mg + Telmisartan 80mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 40mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg + Telmisartan 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Amlodipine</intervention_name>
    <arm_group_label>S-Amlodipine 2.5mg</arm_group_label>
    <arm_group_label>S-Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 years or older&#xD;
&#xD;
          -  stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure&#xD;
             &gt;=95 and &lt;=115 mmHg&#xD;
&#xD;
          -  ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe hypertension defined as: a mean seated cuff diastolic blood pressure &gt;=116mmHg&#xD;
             or a mean seated cuff systolic blood pressure &gt;=200mmHg&#xD;
&#xD;
          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary&#xD;
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)&#xD;
&#xD;
          -  has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or&#xD;
             myocardial infarction, arrhythmia within the past three months&#xD;
&#xD;
          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6&#xD;
             months&#xD;
&#xD;
          -  Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as&#xD;
             defined by fasting glucosylated hemoglobin(HbA1c) &gt; 8%&#xD;
&#xD;
          -  known severe or malignant retinopathy&#xD;
&#xD;
          -  hepatic or renal dysfunction as defined by the following laboratory parameters:&#xD;
             AST/ALT &gt; UNL X 2, serum creatinine &gt; UNL X 1.5&#xD;
&#xD;
          -  acute or chronic inflammatory status need to treatment&#xD;
&#xD;
          -  need to additional antihypertensive drugs during the study&#xD;
&#xD;
          -  need to concomitant medications known to affect blood pressure during the study&#xD;
&#xD;
          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers&#xD;
&#xD;
          -  known hypersensitivity related to either study drug&#xD;
&#xD;
          -  history of drug or alcohol dependency&#xD;
&#xD;
          -  any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of investigational products(ex.&#xD;
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,&#xD;
             active inflammatory bowel syndrome within 12 months prior to screening, currently&#xD;
             active gatritis, ulcers of gastrointetinal/rectal bleeding, impaired pancreatic&#xD;
             fuction such as pancreatitis,obstructions of the urinary tract or difficulty in&#xD;
             voiding)&#xD;
&#xD;
          -  cannot swallow investigational products&#xD;
&#xD;
          -  administration of other study drugs within 4 weeks prior to randomization&#xD;
&#xD;
          -  premenopausal women(last menstration &lt; 1year) not using adequte contraception,&#xD;
             pregnant or breast-feeding&#xD;
&#xD;
          -  history of malignancy including leukemia and lymphoma within the past 5 years&#xD;
&#xD;
          -  in investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital in Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National Uiversity Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DonGuk University International Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kandong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, The catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uijeongbu St. Mary's Hospital, The catholic University of Korea</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>April 22, 2011</last_update_submitted>
  <last_update_submitted_qc>April 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim / Director</name_title>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Factorial</keyword>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

